Yasuhiro Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yasuhiro Suzuki has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Yasufumi Sato
New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan
20 shared publications Mitsuaki Suzuki
8 shared publications- Soichi Kojima
Liver Cancer Prevention Research Unit, RIKEN Center for Integrative Medical Sciences, Saitama, Japan
8 shared publications Yasufumi Sato
Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan
7 shared publicationsYasushi Saga
7 shared publicationsHiroki Miyashita
Department of Vascular Biology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan
6 shared publications
Latest Publications
- Open Access
- 10 July 2023
- Published by Wiley in Cancer Science
- Vol. 114 (9) , 3740-3749
Novel strategy of liver cancer treatment with modified antisense oligonucleotides targeting human vasohibin‐2
Vasohihibin‐2 (VASH2) is a homolog of vasohibin‐1 (VASH1) and is overexpressed in various cancers. Vasohihibin‐2 acts on both cancer cells and cancer microenvironmental cells. Previous analyses have shown that VASH2 promotes cancer progression and abrogation of VASH2 results in significant anticancer effects. We therefore propose VASH2 to be a practical molecular target for cancer treatment. Modifications of antisense oligonucleotide (ASO) such as bridged nucleic acids (BNA)‐based modification increases the specificity and stability of ASO, and are now applied to the development of a number of oligonucleotide‐based drugs. Here we designed human VASH2‐ASOs, selected an optimal one, and developed 2′,4′‐BNA‐based VASH2‐ASO. When systemically administered, naked 2′,4′‐BNA‐based VASH2‐ASO accumulated in the liver and showed its gene‐silencing activity. We then examined the effect of 2′,4′‐BNA‐based VASH2‐ASO in liver cancers. Intraperitoneal injection of naked 2′,4′‐BNA‐based VASH2‐ASO exerted a potent antitumor effect on orthotopically inoculated human hepatocellular carcinoma cells. The same manipulation also showed potent antitumor activity on the splenic inoculation of human colon cancer cells for liver metastasis. These results provide a novel strategy for the treatment of primary as well as metastatic liver cancers by using modified ASOs targeting VASH2.
- 10 July 2023
- Published by Wiley in Cancer Science
- Vol. 114 (9) , 3740-3749
Open AccessNovel strategy of liver cancer treatment with modified antisense oligonucleotides targeting human vasohibin‐2
Vasohihibin‐2 (VASH2) is a homolog of vasohibin‐1 (VASH1) and is overexpressed in various cancers. Vasohihibin‐2 acts on both cancer cells and cancer microenvironmental cells. Previous analyses have shown that VASH2 promotes cancer progression and abrogation of VASH2 results in significant anticancer effects. We therefore propose VASH2 to be a practical molecular target for cancer treatment. Modifications of antisense oligonucleotide (ASO) such as bridged nucleic acids (BNA)‐based modification increases the specificity and stability of ASO, and are now applied to the development of a number of oligonucleotide‐based drugs. Here we designed human VASH2‐ASOs, selected an optimal one, and developed 2′,4′‐BNA‐based VASH2‐ASO. When systemically administered, naked 2′,4′‐BNA‐based VASH2‐ASO accumulated in the liver and showed its gene‐silencing activity. We then examined the effect of 2′,4′‐BNA‐based VASH2‐ASO in liver cancers. Intraperitoneal injection of naked 2′,4′‐BNA‐based VASH2‐ASO exerted a potent antitumor effect on orthotopically inoculated human hepatocellular carcinoma cells. The same manipulation also showed potent antitumor activity on the splenic inoculation of human colon cancer cells for liver metastasis. These results provide a novel strategy for the treatment of primary as well as metastatic liver cancers by using modified ASOs targeting VASH2.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Vasohibin-2 Expressed in Human Serous Ovarian Adenocarcinoma Accelerates Tumor Growth by Promoting Angiogenesis
PDF file - 84K, RT-PCR analysis of VASH2 and SVBP in human ovarian cancer cells and EL-4
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Vasohibin-2 Expressed in Human Serous Ovarian Adenocarcinoma Accelerates Tumor Growth by Promoting Angiogenesis
PDF file - 84K, RT-PCR analysis of VASH2 and SVBP in human ovarian cancer cells and EL-4
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Vasohibin-2 Expressed in Human Serous Ovarian Adenocarcinoma Accelerates Tumor Growth by Promoting Angiogenesis
PDF file - 39K, Possible splicing variants of human VASH2
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Vasohibin-2 Expressed in Human Serous Ovarian Adenocarcinoma Accelerates Tumor Growth by Promoting Angiogenesis
PDF file - 39K, Possible splicing variants of human VASH2
- Open Access
- 16 September 2020
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 76 (10) , 993-1000
The crystal structure of the tetrameric human vasohibin-1–SVBP complex reveals a variable arm region within the structural core
Vasohibins regulate angiogenesis, tumor growth, metastasis and neuronal differentiation. They form a complex with small vasohibin-binding protein (SVBP) and show tubulin tyrosine carboxypeptidase activity. Recent crystal structure determinations of vasohibin–SVBP complexes have provided a molecular basis for complex formation, substrate binding and catalytic activity. However, the regulatory mechanism and dynamics of the complex remain elusive. Here, the crystal structure of the VASH1–SVBP complex and a molecular-dynamics simulation study are reported. The overall structure of the complex was similar to previously reported structures. Importantly, however, the structure revealed a domain-swapped heterotetramer that was formed between twofold symmetry-related molecules. This heterotetramerization was stabilized by the mutual exchange of ten conserved N-terminal residues from the VASH1 structural core, which was intramolecular in other structures. Interestingly, a comparison of this region with previously reported structures revealed that the patterns of hydrogen bonding and hydrophobic interactions vary. In the molecular-dynamics simulations, differences were found between the heterotetramer and heterodimer, where the fluctuation of the N-terminal region in the heterotetramer was suppressed. Thus, heterotetramer formation and flexibility of the N-terminal region may be important for enzyme activity and regulation.
- 16 September 2020
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section D Structural Biology
- Vol. 76 (10) , 993-1000
Open AccessThe crystal structure of the tetrameric human vasohibin-1–SVBP complex reveals a variable arm region within the structural core
Vasohibins regulate angiogenesis, tumor growth, metastasis and neuronal differentiation. They form a complex with small vasohibin-binding protein (SVBP) and show tubulin tyrosine carboxypeptidase activity. Recent crystal structure determinations of vasohibin–SVBP complexes have provided a molecular basis for complex formation, substrate binding and catalytic activity. However, the regulatory mechanism and dynamics of the complex remain elusive. Here, the crystal structure of the VASH1–SVBP complex and a molecular-dynamics simulation study are reported. The overall structure of the complex was similar to previously reported structures. Importantly, however, the structure revealed a domain-swapped heterotetramer that was formed between twofold symmetry-related molecules. This heterotetramerization was stabilized by the mutual exchange of ten conserved N-terminal residues from the VASH1 structural core, which was intramolecular in other structures. Interestingly, a comparison of this region with previously reported structures revealed that the patterns of hydrogen bonding and hydrophobic interactions vary. In the molecular-dynamics simulations, differences were found between the heterotetramer and heterodimer, where the fluctuation of the N-terminal region in the heterotetramer was suppressed. Thus, heterotetramer formation and flexibility of the N-terminal region may be important for enzyme activity and regulation.
- 20 January 2020
- Published by Elsevier in Microbes and Infection
- Vol. 22 (8) , 375-378
The amino-terminal region of dense granule protein 6 of Toxoplasma gondii stimulates IFN-γ production by microglia
- 20 January 2020
- Published by Elsevier in Microbes and Infection
- Vol. 22 (8) , 375-378
The amino-terminal region of dense granule protein 6 of Toxoplasma gondii stimulates IFN-γ production by microglia
- Open Access
- 9 May 2019
- Published by Wiley in Cancer Science
- Vol. 110 (7) , 2296-2308
Vasohibin‐2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma
Vasohibin‐2 (VASH2) is expressed in various cancers and promotes their progression. We recently reported that pancreatic cancer patients with higher VASH2 expression show poorer prognosis. Herein, we sought to characterize the role of VASH2 in pancreatic cancer. We used LSL‐KrasG12D; LSL‐Trp53R172H; Pdx‐1‐Cre (KPC) mice, a mouse model of pancreatic ductal adenocarcinoma (PDAC), and cells isolated from them (KPC cells). Knockdown of Vash2 from PDAC cells did not affect their proliferation, but decreased their migration. When Vash2‐knockdown PDAC cells were orthotopically inoculated, liver metastasis and peritoneal dissemination were reduced, and the survival period was significantly prolonged. When KPC mice were crossed with Vash2‐deficient mice, metastasis was significantly decreased in Vash2‐deficient KPC mice. VASH2 was recently identified to have tubulin carboxypeptidase activity. VASH2 knockdown decreased, whereas VASH2 overexpression increased tubulin detyrosination of PDAC cells, and tubulin carboxypeptidase (TCP) inhibitor parthenolide inhibited VASH2‐induced cell migration. We next clarified its role in the tumor microenvironment. Tumor angiogenesis was significantly abrogated in vivo when VASH2 was knocked down or deleted. We further examined genes downregulated by Vash2 knockdown in KPC cells, and found chemokines and cytokines that were responsible for the recruitment of myeloid derived suppressor cells (MDSC). Indeed, MDSC were accumulated in PDAC of KPC mice, and they were significantly decreased in Vash2‐deficient KPC mice. These findings suggest that VASH2 plays an essential role in the metastasis of PDAC with multiple effects on both cancer cells and the tumor microenvironment, including tubulin detyrosination, tumor angiogenesis and evasion of tumor immunity.
- 9 May 2019
- Published by Wiley in Cancer Science
- Vol. 110 (7) , 2296-2308
Open AccessVasohibin‐2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma
Vasohibin‐2 (VASH2) is expressed in various cancers and promotes their progression. We recently reported that pancreatic cancer patients with higher VASH2 expression show poorer prognosis. Herein, we sought to characterize the role of VASH2 in pancreatic cancer. We used LSL‐KrasG12D; LSL‐Trp53R172H; Pdx‐1‐Cre (KPC) mice, a mouse model of pancreatic ductal adenocarcinoma (PDAC), and cells isolated from them (KPC cells). Knockdown of Vash2 from PDAC cells did not affect their proliferation, but decreased their migration. When Vash2‐knockdown PDAC cells were orthotopically inoculated, liver metastasis and peritoneal dissemination were reduced, and the survival period was significantly prolonged. When KPC mice were crossed with Vash2‐deficient mice, metastasis was significantly decreased in Vash2‐deficient KPC mice. VASH2 was recently identified to have tubulin carboxypeptidase activity. VASH2 knockdown decreased, whereas VASH2 overexpression increased tubulin detyrosination of PDAC cells, and tubulin carboxypeptidase (TCP) inhibitor parthenolide inhibited VASH2‐induced cell migration. We next clarified its role in the tumor microenvironment. Tumor angiogenesis was significantly abrogated in vivo when VASH2 was knocked down or deleted. We further examined genes downregulated by Vash2 knockdown in KPC cells, and found chemokines and cytokines that were responsible for the recruitment of myeloid derived suppressor cells (MDSC). Indeed, MDSC were accumulated in PDAC of KPC mice, and they were significantly decreased in Vash2‐deficient KPC mice. These findings suggest that VASH2 plays an essential role in the metastasis of PDAC with multiple effects on both cancer cells and the tumor microenvironment, including tubulin detyrosination, tumor angiogenesis and evasion of tumor immunity.
- Open Access
- 17 May 2018
- Published by Wiley in Health Science Reports
- Vol. 1 (6) , e40
High preoperative plasma vasohibin‐1 concentration predicts better prognosis in patients with non–small cell lung carcinoma
Background and Aim: Vasohibin‐1 (VASH1) is an angiogenesis inhibitor synthesized and secreted by endothelial cells, whose expression is induced by angiogenic stimuli such as vascular endothelial growth factor. We have previously demonstrated that VASH1 is immunohistochemically evident in endothelial cells in the tumor microenvironment of patients with non–small cell lung cancer (NSCLC) and is positively correlated with that of vascular endothelial growth factor in cancer cells. Here, we determined the preoperative plasma concentration of VASH1 in patients with NSCLC and evaluated the association between the preoperative VASH1 levels and certain outcomes.Methods: We analyzed presurgical plasma VASH1 concentrations in a total of 79 lung cancer patients (51 males and 28 females; 34‐83 y of age; 46 adenocarcinomas, 27 squamous cell carcinomas, and 6 other types) who underwent lung resection. The impact of preoperative VASH1 level was analyzed using clinical characteristics and prognosis.Results: Plasma VASH1 concentration ranged from 34.1 to 1190.4 fmol/mL. We divided the patients into 3 groups according to plasma VASH1 level for this assessment: low VASH1 group (n = 26), medium VASH1 group (n = 27), and high VASH1 group (n = 26). The death and recurrence rates of the high, medium, and low VASH1 groups were 5.5, 16.2, and 12.7 per 100 person‐years, respectively. Multivariate adjusted hazard ratio of death and recurrence of the high VASH1 group was lower than that of the low VASH1 group (hazard ratio 0.42; 95% CI 0.17‐0.99).Conclusion: The present analysis suggests that high preoperative plasma VASH1 concentration is associated with better prognosis in patients with NSCLC. We propose preoperative VASH1 level as a biomarker for the prognosis of patients with non–small cell lung carcinoma.
- 17 May 2018
- Published by Wiley in Health Science Reports
- Vol. 1 (6) , e40
Open AccessHigh preoperative plasma vasohibin‐1 concentration predicts better prognosis in patients with non–small cell lung carcinoma
Background and Aim: Vasohibin‐1 (VASH1) is an angiogenesis inhibitor synthesized and secreted by endothelial cells, whose expression is induced by angiogenic stimuli such as vascular endothelial growth factor. We have previously demonstrated that VASH1 is immunohistochemically evident in endothelial cells in the tumor microenvironment of patients with non–small cell lung cancer (NSCLC) and is positively correlated with that of vascular endothelial growth factor in cancer cells. Here, we determined the preoperative plasma concentration of VASH1 in patients with NSCLC and evaluated the association between the preoperative VASH1 levels and certain outcomes.Methods: We analyzed presurgical plasma VASH1 concentrations in a total of 79 lung cancer patients (51 males and 28 females; 34‐83 y of age; 46 adenocarcinomas, 27 squamous cell carcinomas, and 6 other types) who underwent lung resection. The impact of preoperative VASH1 level was analyzed using clinical characteristics and prognosis.Results: Plasma VASH1 concentration ranged from 34.1 to 1190.4 fmol/mL. We divided the patients into 3 groups according to plasma VASH1 level for this assessment: low VASH1 group (n = 26), medium VASH1 group (n = 27), and high VASH1 group (n = 26). The death and recurrence rates of the high, medium, and low VASH1 groups were 5.5, 16.2, and 12.7 per 100 person‐years, respectively. Multivariate adjusted hazard ratio of death and recurrence of the high VASH1 group was lower than that of the low VASH1 group (hazard ratio 0.42; 95% CI 0.17‐0.99).Conclusion: The present analysis suggests that high preoperative plasma VASH1 concentration is associated with better prognosis in patients with NSCLC. We propose preoperative VASH1 level as a biomarker for the prognosis of patients with non–small cell lung carcinoma.